Avacta Group has established a commercial team of three people in the US including the appointment of Dr Matthew Vincent as vice-president therapeutics business development.

It said: 'In order to exploit the rapidly growing interest in Avacta's proprietary Affimer alternative to antibodies, and to further grow the pipeline of evaluations and collaborations, the group has taken the strategic decision to establish a permanent US business development team.

'The new US team comprises three individuals: two business development executives based in San Diego, CA and Philadelphia, PA each with a broad business development remit for Affimer technology across diagnostic, research and therapeutic markets, and Dr Matthew Vincent who has been appointed as vice-president therapeutics business development based in Boston Massachusetts.'

The new US team joins the commercial team headed by chief commercial officer, Dr Philippe Cotrel who was previously commercial director of Abcam and who joined Avatca in 2016.

It said the expansion in the US brought the total in that team to eight including UK/EU business development individuals, marketing and customer support.